Genelux Corporation (GNLX) vs MaxCyte, Inc. (MXCT)
A side-by-side comparison of Genelux Corporation and MaxCyte, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
GNLX
Genelux Corporation
$2.56HealthcareDelayed quote: Oct 6, 2026, 10:50 AM EDT
MXCT
MaxCyte, Inc.
$1.07HealthcareDelayed quote: Oct 6, 2026, 10:48 AM EDT
Total return — GNLX vs MXCT
growth of $100 · dividends reinvested · last 4yGNLX -57.7% (-19.4%/yr)MXCT -81.2% (-34.1%/yr)GNLX compounded faster over this window
GNLX MXCT
GNLX vs MXCT: by the numbers
- •GNLX is the larger company ($115M vs $115M market cap).
- •Both run net losses; MXCT's is the smaller (-114.77% vs -422412.50% net margin).
Metrics side by side
Valuation
| Metric | GNLX | MXCT |
|---|---|---|
| P/S ratio | 14348.93 | 3.69 |
| P/B ratio | 7.12 | 0.72 |
Profitability
| Metric | GNLX | MXCT |
|---|---|---|
| Gross margin | -7075.00% | 79.43% |
| Operating margin | -415175.00% | -137.12% |
| Net margin | -422412.50% | -114.77% |
| ROE | -209.73% | -22.45% |
| ROIC | -192.18% | -19.83% |
Growth (annualized)
| Metric | GNLX | MXCT |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 1.46% |
| Total return CAGR (5Y) | N/A | -37.32% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.